Brigham and Women's Hospital, Inc.
Making Lung Cancer Responsive to Treatment for Other Cancers
Current research for new lung cancer treatment relies on the development of drugs that inhibit molecules that are overproduced in cancer, such as mTOR. While mTOR inhibitors, such as the drug everolimus (Afinitor), have been approved for several types of cancers, they have shown limited benefit in lung cancer treatment. The tumor suppressor gene p53 is frequently lost or mutated in lung cancer. We will explore how restoring the tumor suppressor gene p53 could sensitize lung cancer cells with loss of p53 functions to everolimus. We hope that a better understanding of targeting p53 and mTOR will lead to the development of novel combination therapies for better treatment of lung cancers.